Author name: fwadmin

Rethinking Brexit, the triple lock and other follies isn’t politically viable now but will be in 2029

Novo Nordisk plans to invest $4.1 billion to build a second fill and finishing manufacturing facility in Clayton, N.C., as demand for weight-loss drugs show no signs of letting up.

The jet manufacturer has proposed using mostly stock to reacquire the supplier.

With the deal, Brookfield aims to bolster exposure to renewables and battery-storage technology and to accelerate Neoen’s portfolio expansion.

Blockbuster obesity drug Wegovy has been approved in China, opening the door for maker Novo Nordisk to begin selling it in the world’s second-largest economy, where the appetite for similar treatments is surging.